Coagulation Factor Concentrates Market Is Predicted to Climb to US$ 11.4 Billion by 2027

In 2022, the global coagulation factor concentrates market is valued at US$ 7.8 billion and is predicted to climb to US$ 11.4 billion by the end of 2027. Worldwide demand for coagulation factor concentrates is anticipated to rise at a high-value CAGR of 7.8% over the next five years. Coagulation factor XIII is anticipated to witness high demand owing to the rising incidence of hemophilia and its better-quality safety profile than other factor concentrates.

The offer in this portion accompanies many open doors including fabricating items, appropriation, retail, and showcasing administrations. Broad rounds of essential and far-reaching optional exploration have been utilized by the examiners at Fact.MR to show up at different assessments and projections for the Demand of Coagulation Factor Concentrates Market both at worldwide and provincial levels.

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗮 𝗦𝗮𝗺𝗽𝗹𝗲 𝗖𝗼𝗽𝘆 𝗼𝗳 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁: -
https://www.factmr.com/connectus/sample?flag=S&rep_id=7677

"𝗡𝗼𝗿𝘁𝗵 𝗔𝗺𝗲𝗿𝗶𝗰𝗮 & 𝗘𝘂𝗿𝗼𝗽𝗲 𝘁𝗼 𝗦𝗽𝗲𝗮𝗿𝗵𝗲𝗮𝗱 𝗚𝗹𝗼𝗯𝗮𝗹 𝗖𝗼𝗮𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗙𝗮𝗰𝘁𝗼𝗿 𝗖𝗼𝗻𝗰𝗲𝗻𝘁𝗿𝗮𝘁𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗚𝗿𝗼𝘄𝘁𝗵"

The North America coagulation factor concentrates market is projected to account for a prominent market share in the global industry landscape throughout the forecast period.

Rapid adoption of novel treatments, the presence of developed healthcare infrastructure, and increasing investments in the healthcare research and development sector are expected to prominently augment coagulation factor concentrate demand in this region through 2027. The market for coagulation factor concentrates in Canada is predicted to evolve at a CAGR of 6.4% over the next five years.

Investments to improve healthcare infrastructure and increasing supportive government initiatives to boost awareness of blood disorders are expected to favor coagulation factor concentrate sales in Europe over the coming years. Key countries that coagulation factor concentrate suppliers should keep an eye out for in this region are France, Italy, Germany, and the United Kingdom.

The Germany coagulation factor concentrates market is anticipated to exhibit expansion at a CAGR of around 4.5% through 2027.

The Asia Pacific coagulation factor concentrates market is anticipated to be driven by an increasing blood-related disorder-affected patient pool and rising investments in healthcare infrastructure development. India is anticipated to be one of the key markets for coagulation factor concentrates owing to the high prevalence of hemophilia in the country.

The coagulation factor concentrates market in China is also expected to be highly opportune owing to the rising focus on healthcare infrastructure development and rising awareness of blood disorders. Demand for coagulation factor concentrates in China is anticipated to rise at a CAGR of 12% over the next five years and hold a value of US$ 2.5 billion by the end of 2027.

𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 :

In their pursuit of revenue expansion, providers of coagulation factor concentrates are actively seeking new product approvals from regulatory authorities.

A significant milestone was reached in July 2022, when Novo Nordisk, a leading Danish multinational pharmaceutical firm, announced the approval of REBINYN® by the United States Food and Drug Administration (FDA). REBINYN, a GlycoPEGylated Coagulation Factor IX, is a recombinant DNA-derived concentrate intended for regular prophylaxis in both adults and children.

Furthermore, this market study on the coagulation factor concentrates industry highlights recent noteworthy developments from key players including Baxter International Inc., Octapharma, LFB, Biotest, Green Cross Corporation, Shanghai RAAS Blood Products, and Sanquin. These developments underscore the dynamic nature of the industry and the efforts of these companies to advance their offerings.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: -

CSL Behring
Shire
Kedrion S.P.A.
Grifols
Baxter International Inc.
Octapharma
LFB
Novo Nordisk A/S
Biotest
Green Cross Corporation
Shanghai RAAS Blood Products
Sanquin
Bio Product Laboratory
Medscape

𝗞𝗲𝘆 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗖𝗼𝗮𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗙𝗮𝗰𝘁𝗼𝗿 𝗖𝗼𝗻𝗰𝗲𝗻𝘁𝗿𝗮𝘁𝗲𝘀 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵

𝗕𝘆 𝗧𝘆𝗽𝗲 :
Coagulation Factor IX
Coagulation Factor XIII
Other Types

𝗕𝘆 𝗘𝗻𝗱 𝗨𝘀𝗲𝗿 :
Hospitals & Clinics
Research Laboratories
Academic Institutions

𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝘀

North America (U.S., Canada)
Latin America (Brazil, Mexico, Argentina, Chile, Peru, Rest of LATAM)
EU - (Germany, France, Italy, Spain), UK, BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
CIS & Russia
Japan
Asia Pacific Excluding Japan (Greater China, India, S. Korea, ASEAN Countries, Rest of APEJ)

𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲 𝘁𝗵𝗶𝘀 𝗿𝗲𝗽𝗼𝗿𝘁 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7677

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.

This release was published on openPR.